Pharmafile Logo

News and Press Releases

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance. 10 March...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

European Commission approves AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Codexis signs agreement to manufacture 50g siRNA using its ECO Synthesis Manufacturing Platform

4 March 2026 -- California, US -- Codexis, Inc, a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into an agreement with...

Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2026

Codexis
200 Penobscot Drive
 Redwood City, California 94063
 650-421-8100

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles 26 February 2026 -- Massachusetts, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 3, 2026

Curium Pharma
contactus@curiumpharma.com
Perceptive 55 Blue Sky Drive Burlington Massachusetts 01803 United States

BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure

Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds Aurase shows dual action on chronic wound debridement and healing SolasCure preparing fund raising for...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 25, 2026

BRAINBiotech
public@brain-biotech.com
Darmstädter Straße 34 – 36 64673 Zwingenberg Deutschland

SolasCure completes phase II clinical trial, demonstrating accelerated healing with Aurase Wound Gel

Aurase Wound Gel shows 22x faster debridement and 7x faster healing compared to standard of care in sloughy venous leg ulcers, supporting advancement to the next phase of development Data...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 24, 2026

SolasCure
wellington house East Rd, Petersfield, Cambridge CB1 1BH

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026

9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose 17 February 2026 -- Oslo, Norway -- Oncoinvent, a biotech...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026

Oncoinvent
oncoinvent@oncoinvent.com
Gullhaugveien 7 0484 Oslo Norway

Thermo Fisher Scientific Expands Real-World Data Interoperability and Linkage Through Strategic Collaboration with Datavant

11 February 2026 -- Massachusetts, US -- Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with Datavant, the data collaboration platform trusted for healthcare, to make...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2026

Thermo Fisher Scientific
168 Third Avenue Waltham, MA 02451

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

ACES-EMB is the first randomized-controlled trial to compare dd-cfDNA surveillance to routine biopsy in organ transplantation, highlighting the benefits of Prospera in organ rejection 28 January 2026 -- Texas, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2026

Natera
13011 McCallen Pass Building A Suite 100 Austin, TX 78753

Johnson & Johnson receives CHMP positive opinion for AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen as a new standard...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Bial Achieves Key Milestone in Phase 2b ACTIVATE Study ofBIA 28-6156 in GBA1-Associated Parkinson’s Disease

75% of patients have completed the Week 78 Last Study Visit Topline results expected in mid-2026 27 January 2026 -- Porto, Portugal -- Bial, an innovation-driven biopharmaceutical company focused on...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 27, 2026

Bial
À Avenida da Siderurgia Nacional 4745-457 Coronado (S. Romão e S. Mamede) Portugal

Journal of Prevention of Alzheimer’s Disease publishes trial results showing HMTM potentially offers accessible oral treatment option for patients with early Alzheimer’s disease

26 January 2026 -- Scotland, UK -- TauRx Therapeutics Management Ltd today announced results from its Phase III LUCIDITY trial evaluating the efficacy and safety of hydromethylthionine mesylate (HMTM) in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 26, 2026

TauRx Therapeutics
andy.groundwater@taurx.com
395 King Street Aberdeen AB24 5RP United Kingdom

MetP Pharma’s Enabling Technology Creates a New Brain-Targeted GLP-1 Opportunity

Preclinical data in rats demonstrate dose-dependent and rapid brain targeting of intranasal semaglutide with low systemic exposure 22 January 2026 -- Emmetten, Switzerland -- MetP Pharma AG, a pioneer in nose-to-brain...

Category: Biotechnology, Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: January 22, 2026

MetP Pharma
info@mattern-pharma.com
Schynweg 7 Office: St. Anna-Weg 16 P.O.Box 138 6376 Emmetten / Switzerland

Dawnzera (donidalorsen) granted European Union marketing authorisation for the prevention of hereditary angioedema

Donidalorsen is a first-in-class RNA-targeted prophylactic therapy for patients with hereditary angioedema (HAE) Donidalorsen demonstrated a significant reduction in HAE attack rate compared with placebo in the Phase 3 OASIS-HAE...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 21, 2026

Otsuka Pharmaceutical Europe Ltd
medical.information@otsuka-europe.com
Gallions Wexham Springs Framewood Road Wexham SL3 6PJ

Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis

20 January 2026 -- Sandwich, UK -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 20, 2026

Levicept
info@levicept.com
Innovation House Discovery Park Ramsgate Road Sandwich Kent CT13 9ND